

CLAIMS

What is claimed is:

1. ~~Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating migraine in a patient in need thereof, wherein said medicament provide decrease in the number of migraines per month for said patient of at least 20%.~~
2. ~~The use of claim 1 wherein the decrease in the number of migraines per month for said patient of at least 30%.~~
3. ~~The use of claim 2 wherein the decrease in the number of migraines per month for said patient of at least 40%.~~
4. ~~Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a migraine in a patient in need thereof, wherein said medicament provide Pain Freedom of the pharmaceutical composition of at about 30% greater than placebo.~~
5. ~~The use of claim 1 wherein the Pain Freedom of the pharmaceutical composition is at least about 50% greater than placebo.~~
6. ~~The use of claim 4 wherein the Pain Freedom of the pharmaceutical composition is from about 30-75% greater than placebo.~~
7. ~~The use of claim 6 wherein the Pain Freedom of the pharmaceutical composition is from about 35-65% greater than placebo.~~
8. ~~Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof in the~~

~~manufacture of a medicament for treating migraine in a patient in need thereof, wherein said medicament provide Freedom from MBS of the pharmaceutical composition of at about 30% greater than placebo.~~

~~9. — The use of claim 8 wherein the Freedom from MBS of the pharmaceutical composition is at least about 40% greater than placebo.~~

~~10. — The use of claim 8 wherein the Freedom from MBS of the pharmaceutical composition is from about 30-50% greater than placebo.~~

~~11. — The use of claim 4 which provides an AUC_{0-t} of from about 80-125% of 5000 (hr*ng/mL).~~

~~12. — The use of claim 4 which provides a C_{max} of from about 80-125% of 835 (ng/mL).~~

~~13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof, wherein the composition is in the form of an oral solid molded fast-dispersing dosage form~~order to provide an AUC_{0-t} of from about 80-125% of 5000 (hr*ng/mL).~~~~

~~214. The pharmaceutical composition of claim 13, which comprises about 75 mg of rimegepant or a pharmaceutically acceptable salt thereof.~~

~~315. The pharmaceutical composition of claim 13, wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt.~~

~~416. The pharmaceutical composition of claim 13 in the form of a tablet.~~

~~17. — The pharmaceutical composition of claim 16 comprising from about 50-60 wt% rimegepant hemisulfate sesquihydrate, about 30-35 wt% microcrystalline cellulose, about 2-7 wt% hydroxypropyl cellulose, about 3-7 wt% croscarmellose sodium, and about 0.1-1.0 wt% magnesium stearate.~~

18. ~~The pharmaceutical composition of claim 17 comprising about 57.1 wt% rimegepant hemisulfate sesquihydrate, about 33.4 wt% microcrystalline cellulose, about 4.0 wt% hydroxypropyl cellulose, about 5.0 wt% croscarmellose sodium, and about 0.5 wt% magnesium stearate.~~

19. ~~The pharmaceutical composition of claim 13 in the form of an oral solid molded fast-dispersing dosage form.~~

5. The pharmaceutical composition of claim 1, that provides an AUC_{0-t} of from 80-125% of 5000 (hr*ng/mL).

620. The pharmaceutical composition of claim 19, comprising from ~~about~~ 70-80 weight% rimegepant hemisulfate sesquihydrate, ~~about~~ 10-20 weight% fish gelatin, ~~about~~ 10-20 weight% of a filler, and 0.1-5.0 weight% of a flavorant.

7. The pharmaceutical composition of claim 1, further comprising gelatin as a carrier.

821. The pharmaceutical composition of claim 620, wherein the filler is mannitol.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is capable of disintegrating or dispersing within an interval selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed in contact with a fluid.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a CGRP receptor antagonist, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in a form of an oral solid molded fast-dispersing dosage form.

11. The pharmaceutical composition of claim 10, wherein the CGRP receptor antagonist is selected from olcegepant, telcagepant, ubrogepant, atogepant, and rimegepant.

12. The pharmaceutical composition of claim 10, further comprising gelatin as a carrier.

13. The pharmaceutical composition of claim 10, further comprising mannitol as a filler.
14. The pharmaceutical composition of claim 10, comprising from 70-80 weight% of the CGRP antagonist, 10-20 weight% fish gelatin, 10-20 weight% of a filler, and 0.1-5.0 weight% of a flavorant.
15. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is capable of disintegrating or dispersing within an interval selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed in contact with a fluid.
16. The pharmaceutical composition of claim 15, wherein the fluid comprises saliva.